- Home
- BBNX vs GLUE Comparison
BBNX vs GLUE Comparison
Compare BBNX & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBNX | GLUE |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BBNX | GLUE |
|---|---|---|
| Price | $29.73 | $16.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $28.09 | $15.00 |
| AVG Volume (30 Days) | 672.2K | ★ 812.4K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $88,570,000.00 | ★ $181,538,000.00 |
| Revenue This Year | $52.13 | $81.52 |
| Revenue Next Year | $36.16 | N/A |
| P/E Ratio | ★ N/A | $64.61 |
| Revenue Growth | 67.01 | ★ 1112.27 |
| 52 Week Low | $8.89 | $3.50 |
| 52 Week High | $32.71 | $18.15 |
Technical Indicators
Market Signals| Indicator | BBNX | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 58.98 |
| Support Level | $28.00 | $15.21 |
| Resistance Level | $30.50 | $17.75 |
| Average True Range (ATR) | 1.82 | 0.88 |
| MACD | -0.26 | -0.17 |
| Stochastic Oscillator | 38.33 | 42.86 |
Price Performance
Historical ComparisonAbout BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.